Medical Oncologist
Your treatment timeline
How Long Will You Stay — on Pazopanib?
Pazopanib is not a fixed-course treatment like chemotherapy. You take it every day and continue for as long as it is working and your body is tolerating it — your oncologist makes that call based on regular scans, not a calendar.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- No fixed end date — There is no set number of weeks or cycles. The drug continues as long as it is working.
- Scans decide, not the calendar — Response is reassessed by imaging every few months. That scan determines whether you continue.
- Side effects can change the plan — Unmanageable side effects are a valid reason to reduce the dose, take a break, or stop.
- Stopping is not failure — If pazopanib stops working or cannot be tolerated, there are usually other treatment options to discuss.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Pazopanib is taken every day until your scans show the disease has grown or spread, or until side effects become too difficult to manage. NCCN guidance describes this as continuing until disease progression or unacceptable toxicity. There is no fixed number of weeks or cycles — the duration is decided scan by scan.
What does 'take it until it stops working' actually mean?
Pazopanib is a targeted therapy taken as a daily tablet. Unlike chemotherapy given in numbered cycles, it runs continuously — you take it every day without a planned stop date.
Your oncologist monitors the disease with regular scans, typically a CT scan every few months. As long as the scan shows the tumour is stable or smaller, you continue.
The word 'working' means the disease is not growing. The tumour does not have to disappear — holding steady counts as a meaningful response.
What are the reasons pazopanib stops?
The three stopping rules are disease progression, unacceptable side effects, and your own informed choice after discussion with your team.
Disease progression means a scan shows the tumour has grown beyond a defined threshold, or new tumour sites have appeared. When this happens, your oncologist will discuss what the next treatment option looks like.
Unacceptable side effects do not always mean stopping completely. A dose reduction often controls the problem and allows treatment to continue. A short break is another option. Your team will help you find the approach that keeps you on treatment safely.
What is checked at each visit while you are on pazopanib?
- Blood pressureHypertension is common on pazopanib. Your team checks it at every visit and may prescribe or adjust blood pressure medicine.
- Liver function testsPazopanib can affect the liver. A blood test checks liver enzyme levels, particularly in the first months of treatment.
- Thyroid functionHypothyroidism can develop during treatment. A blood test checks thyroid hormone levels periodically.
- Full blood countChecked regularly to look for changes in blood cell counts.
- Symptoms and quality of lifeYour team will ask how you are feeling — specifically about fatigue, hand-foot skin reaction, nausea, and appetite.
- Scan resultsAt imaging visits, the scan is compared against your baseline to decide whether treatment is continuing to work.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
Words your team will use about your treatment duration
- Progression
- The tumour has grown beyond a set threshold on imaging, or new tumour sites have appeared. This is the most common reason to stop pazopanib.
- Stable disease
- The tumour has not grown significantly and has not shrunk significantly. Stable disease is a valid treatment response — it means the drug is holding things in place.
- Partial response
- The tumour has shrunk by a meaningful amount on imaging. Treatment continues as long as this response is maintained.
- Dose reduction
- Taking a lower daily amount of pazopanib to manage side effects while keeping treatment going.
- Treatment break
- A planned pause in pazopanib, usually to allow a side effect to settle, with the intention of restarting.
- Unacceptable toxicity
- Side effects severe enough that continuing at any dose would cause more harm than the treatment is likely to provide.
Questions about how long you will take pazopanib
Is there a typical length of time people stay on pazopanib?
Duration varies considerably from person to person, and no fixed figure applies to everyone. What guides the decision is not a timeline but a scan result. Some people stay on pazopanib for many months, and some for longer, while others find it stops working sooner. Your oncologist cannot tell you in advance how long it will work — the answer comes from successive scans, not a prediction made at the start of treatment.
Can I take a break if the side effects are bad?
Yes, a planned break is a recognised management strategy, not a sign of giving up. Side effects such as severe fatigue, hand-foot skin reaction, or high blood pressure that cannot be controlled with other medicines are all reasons your team may suggest pausing. The aim is to let the side effect settle and then restart, often at a slightly lower dose. Tell your team before stopping on your own — an unplanned gap without their knowledge changes how they monitor you.
What happens when pazopanib stops working?
Your oncologist will review the scan and explain what has changed. A progression finding opens a conversation about what the next treatment option is. Several other treatments may be appropriate depending on your cancer type, how you have tolerated pazopanib, and what has changed on the scan. Being told pazopanib is no longer working is not the same as being told there are no options — it means moving to the next step in your plan.
Can I restart pazopanib after stopping?
In some situations, yes. If treatment was stopped because of a side effect that has now resolved, your oncologist may consider restarting, often at a lower dose. If it was stopped because of progression, restarting the same drug is generally not the recommended approach, because the disease has already shown it can grow through it. This is a decision made case by case, and your team is the right person to ask for your specific situation.
Does taking pazopanib for longer mean it is working better?
Longer duration means the treatment is continuing to hold the disease in check, which is a good sign. But there is no benefit to continuing beyond the point where it stops working — your oncologist will stop it when the scan shows progression, regardless of how long you have been on it. The goal of monitoring is to make that call at the right time: early enough that the next option can start promptly, without stopping prematurely when the drug is still working.
Did you know?
Pazopanib is taken as a tablet at home, not given by infusion in a clinic. Treatment runs continuously through your daily routine, without hospital admissions for each dose.
Regular monitoring — blood tests and scans — is what makes this safe. Those appointments are how your team catches problems early while you continue treatment at home.
Source: NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer
Explore 75 more Kidney, Ovarian & Sarcoma Targeted Medicines topics
Drug Deep Dive: Pazopanib (Votrient)
- Diarrhoea and Blood Pressure Rise on Pazopanib
- Diet and Nutrition While on Pazopanib
- Drug, Food and Supplement Interactions With Pazopanib
- Fertility, Pregnancy and Contraception on Pazopanib
- Hair Turning White and Skin Lightening on Pazopanib
- How Does Pazopanib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Pazopanib Take to Work?
- How Long Will You Stay on Pazopanib?
- Liver Toxicity on Pazopanib: Why LFTs Are Checked Every Two Weeks
- Pazopanib (Votrient, Pazonib): The Complete Patient Guide
- Pazopanib Combinations: Why It Is Usually Given Alone
- Pazopanib Myths: Hair Colour, Liver Damage and Stopping Early
- Pazopanib Price in India: Brand, Generic and Monthly Cost
- Pazopanib Side Effects: The Complete List and Timeline
- Pazopanib Success Rate and Survival: An Honest Look at the Numbers
- Pazopanib for Soft Tissue Sarcoma: What It Can and Cannot Do
- Pazopanib in Elderly Patients and Those With Other Illnesses
- Pazopanib in Kidney Cancer vs Sarcoma: Two Different Treatment Goals
- Pazopanib vs Sunitinib: Comparing Toxicity and Quality of Life
- Taking Pazopanib on an Empty Stomach: Why the Timing Rule Exists
- Tests and Monitoring While You Are on Pazopanib
- When Pazopanib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Pazopanib? Kidney Cancer and Soft Tissue Sarcoma
- Will Insurance or a Government Scheme Pay for Pazopanib?
- Work, Travel and Daily Life on Pazopanib
Drug Deep Dive: Olaparib (Lynparza)
- Adjuvant Olaparib After Early Breast Cancer Surgery
- Anaemia and Extreme Fatigue on Olaparib
- Blood Cancer Risk After Long-Term Olaparib: How Real Is It?
- Diet and Nutrition While on Olaparib
- Drug, Food and Supplement Interactions With Olaparib
- Fertility, Pregnancy and Contraception on Olaparib
- How Does Olaparib Work? The PARP Inhibitor Explained
- How Long Does Olaparib Take to Work?
- How Long Will You Stay on Olaparib?
- Maintenance Olaparib: Taking a Drug When There Is No Visible Cancer
- Nausea on Olaparib: Managing the Most Common Side Effect
- Olaparib (Lynparza, Olanib): The Complete Patient Guide
- Olaparib Myths: 'Only for BRCA', 'It's Chemo', 'It Causes Cancer'
- Olaparib Price in India: Brand, Generic and Monthly Cost
- Olaparib Side Effects: The Complete List and Timeline
- Olaparib Success Rate and Survival: An Honest Look at the Numbers
- Olaparib With Bevacizumab or Hormone Therapy: Combination Regimens
- Olaparib in Elderly Patients and Those With Other Illnesses
- Olaparib vs Niraparib vs Talazoparib: Comparing PARP Inhibitors
- Taking Olaparib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Olaparib
- When Olaparib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Olaparib? BRCA-Mutated Ovarian, Breast, Prostate and Pancreatic Cancer
- Will Insurance or a Government Scheme Pay for Olaparib?
- Work, Travel and Daily Life on Olaparib
Drug Deep Dive: Sunitinib (Sutent)
- Diet and Nutrition While on Sunitinib
- Drug, Food and Supplement Interactions With Sunitinib
- Fertility, Pregnancy and Contraception on Sunitinib
- Hand-Foot Skin Reaction on Sunitinib: Prevention From Day One
- How Does Sunitinib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Sunitinib Take to Work?
- How Long Will You Stay on Sunitinib?
- Mouth Sores, Taste Loss and Yellow Skin Discolouration on Sunitinib
- Sunitinib (Sutent, Sunitix): The Complete Patient Guide
- Sunitinib After Kidney Surgery and for GIST: Two Different Settings
- Sunitinib Myths: Hair Colour Change, Dose Cuts and 'Weaker Treatment'
- Sunitinib Price in India: Brand, Generic and Monthly Cost
- Sunitinib Side Effects: The Complete List and Timeline
- Sunitinib Success Rate and Survival: An Honest Look at the Numbers
- Sunitinib and Immunotherapy: Where Combinations Fit in Kidney Cancer
- Sunitinib in Elderly Patients and Those With Other Illnesses
- Sunitinib vs Pazopanib vs Cabozantinib for Kidney Cancer
- Taking Sunitinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Sunitinib
- The 4-Weeks-On, 2-Weeks-Off Sunitinib Schedule and the 2/1 Alternative
- Thyroid Failure and Fatigue on Sunitinib: The Test to Repeat Every Cycle
- When Sunitinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Sunitinib? Kidney Cancer, GIST and Pancreatic Neuroendocrine Tumours
- Will Insurance or a Government Scheme Pay for Sunitinib?
- Work, Travel and Daily Life on Sunitinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
How will I know if pazopanib has stopped working?
You will usually not feel it change. Progression is detected on imaging, not by a worsening of symptoms in most cases. This is why the scan schedule matters — it is the mechanism by which your team finds out whether the drug is still holding the disease. If your scan shows the tumour has grown beyond a defined threshold, or new sites have appeared, your team will tell you and explain what happens next.
What if I feel well — do I still need to keep taking it?
Yes. Feeling well on pazopanib usually means the treatment is managing the disease, and stopping because you feel good can allow the tumour to grow unchecked. The decision to continue or stop is based on scan findings and blood test results, not on how you feel day to day. If side effects are tolerable and scans are stable, continuing is the recommended approach.
Can my oncologist predict at the start how long I will need it?
Not with reliable precision. Duration depends on how your individual tumour responds, which cannot be known before treatment starts. Your oncologist can explain what responses have been observed across patient populations in clinical trials, as reported by bodies such as ASCO and ESMO, but that population-level information does not predict your individual duration. The answer comes from your own successive scans.
Is stopping pazopanib my choice to make?
Yes, stopping is always your choice. What your oncologist will want to do is make sure you have a clear picture of what stopping means for your disease before you decide. If you are considering stopping because of side effects, there may be options — a dose reduction, a short break, or medicines to manage the effects — that make continuing more comfortable. Tell your team first so the decision is fully informed.
Do I take pazopanib on the days I have scans or blood tests?
Ask your team, because the guidance may vary by centre and by what tests are being done. In general pazopanib is taken every day including test days, but some blood tests and scans have specific requirements around food and timing. Your oncologist or pharmacist will tell you if anything changes on a test day. When in doubt, check the morning of the appointment rather than skipping a dose on your own judgment.
What is a dose reduction and does it mean treatment is failing?
A dose reduction means taking a lower daily amount of pazopanib to bring side effects to a manageable level. It does not mean the drug has stopped working. Dose reductions are a standard and planned part of how targeted therapies are managed — the drug continues to act on the tumour at the lower dose. Many people spend part or all of their time on pazopanib at a reduced dose and continue to have stable scan results.